CHANGES OF HEPCIDIN CONCENTRATIONS IN SERUM AND ITS EXPRESSION IN TUMOR CELLS DEPENDING ON THE CLINICOPATHOLOGICAL FEATURES OF BREAST CANCER
Keywords:
breast cancer, hepcidin, molecular subtype of breast cancer, malignancy, anemia, hemoglobin.Abstract
Summary. Objective: to determine the hepcidin (HEPC)
concentration in serum and its expression in tumor cells
depending on the clinico-pathological features of breast
cancer and analysis of the sHEPC and tHEPC communication with the presence of anemia in patients with
breast cancer. Object and methods: samples of operational material and samples of blood serum of 65 patients
with breast cancer stage I–II (including 18 patients with
anemia) aged 23 to 89 years. General clinical, histological, іmmunohistochemical, ELISA and statistical methods. Results: significant variability was shown in the concentration of sHEPC in patients with breast cancer, indicating the use sHEPC as an individual indicator of
iron distortion metabolism in breast cancer patients. The
data shows the correlation between sHEPC levels and
tHEPC expression in breast cancer patients with stage II
and histological structure. tHEPC expression in the tumor cells directly correlates with the metastatic lesion of
regional lymph nodes and a low degree of differentiation
of breast cancer. Special characteristics of sHEPC and
tHEPC depending on the molecular subtype of breast
cancer were determined. А direct correlation between the
sHEPC concentration and anemia as also reverse correlation with the level of hemoglobin in patients with breast
cancer was demonstrated. Conclusions: the given data reflect the importance role of HEPC in the progression of
malignant disease and its association with more aggressive forms of breast cancer (basal molecular subtype) that
gives grounds to consider sHEPS and tHEPS as diagnostic markers of iron disorders homeostasis under the manifestation of breast cancer, including patients with anemia.
References
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015; 24 (10): 1495–506.
Ludwig H, Muldur E, Endler G, et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96: (Suppl 2): 409.
Луговской СП, Лубянова ИП, Клименко ПП. Особенности метаболизма железа и его роль в процессах канцерогенеза. Укр журн проблем мед праці 2013; 2 (35): 55–63.
Чехун СВ, Лук’янова НЮ, Собченко СО та ін. Зв’язок ироваткового та пухлинного феритину з клініко-морфологічними характеристиками та молекулярним типом
пухлин у хворих на рак молочної залози. Онкология 2014; 16 (4): 275–82.
Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823 (9):1434–43.
Pusatcioglu CK, Nemeth E, Giamila Fantuzzi, et al. Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond) 2014; 11: 21.
Kamai T, Tomosugi N, Abe H, et al. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 2009; 9: 270.
Orlandi R, Bortoli M De, Cinisellі CM. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol 2014; 25 (2): 352–7.
Winand FJ, Boegemann M, Gallitz I, et al. GDF15 and hepcidin as prognostic factors in patients with prostate cancer. J Mol Biomark Diagn 2014; 5 (6): 199.
Лук’янова НЮ, Яловенко ТМ, Чехун ВФ. Особливості експресії гепсидину у хворих на рак молочної залози.
Онкология 2015; 17 (4): 258–62.
Чехун ВФ, Яловенко ТН, Павлова АА, Лукьянова НЮ. Клиническое значение уровня металлосодержащих белков в сыворотке крови больных раком молочной железы. Онкол журн 2016; 2 (38): 7–13.
Яловенко ТМ. Прогностичне значення пухлинного та сироваткового гепсидину у хворих на рак молочної залози. Матеріали науково-практичної конференції молодих вчених «Перспективи діагностики та лікування онкологічної патології». Клин онкол 2016; 2 (22): 80.
Rodgers GM, Becker PS, Blinder M. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;
: 628–53.
Guido D. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res 2013; 48 (1): 10–15.
Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80 (3): 240–4.
Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008; 112 (10): 4292–7.
Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus
cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13 (1): 33–42.
Choi CH, Kang H, Kim WY, et al. Prognostic value of base line lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Biol Phys 2008; 71 (1): 199–204.
Guido D. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res 2013; 48 (1): 10–15.
Kerkhoff AD, Meintjes G, Burton R, et al. Relationship between blood concentrations of hepcidin and anemia severity, mycobacterial burden, and mortality among patients with HIVassociated tuberculosis. J Infect Dis 2016; 213 (1): 61–70.
Sun Y, Liang F, Cao W, et al. Prognostic value of differentiated clusters in invasive breast cancer. World J Surg Oncol
; 12: 310.
Pan XT, Lu Y, Cheng X, et al. Expression and significance of hepcidin, lps and il-6 in the patients with cancer-related anemia. J Mod Lab Med 2012; 1: 55–7.
Orlandi R, Bortoli M De, Cinisellі C M. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol 2014; 25: 352–7.
Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev 2009; 23: 95–104.
Cohen LA, Gutierrez L, Weiss A, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010; 116: 1574–84.
Alkhateeb AA, Leitzel K, Ali SM, et al. Elevation in inflammatory serum biomarkers predicts response to trastuzumabcontaining therapy. PLoS One 2012; 7: e51379.
Mecklenburg I, Reznik D, Fasler-Kan E, et al. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis 2014; 8: 1392–7.
Ward DG, Roberts K, Brookes MJ, et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 2008; 14: 1339–45.
Fargion S, Valenti L, Fracanzani AL. Role of iron in hepatocellular carcinoma. Clinic Liver Dis 2014; 3 (5): 108–10.
Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117 (17): 4425–33.
